MAP2K7 and colorectal carcinoma: In these experiments, treatments with SB202190 and/or PD98059, which we characterized in a previous report [21,22], were used as a control for the impact of p38α and/or MEK inhibition on CRC cells (Figure 4g,h and Figure S3a,b).